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Abstract 
Improving regulatory confidence in, and acceptance of, a prediction of toxicity from a quantitative 
structure-activity relationship (QSAR) requires assessment of its uncertainty and determination of 
whether the uncertainty is acceptable. Thus, it is crucial to identify potential uncertainties 
fundamental to QSAR predictions. Based on expert review, sources of uncertainties, variabilities and 
biases, as well as areas of influence in QSARs for toxicity prediction were established. These were 
grouped into three thematic areas: uncertainties, variabilities, potential biases and influences 
associated with 1) the creation of the QSAR, 2) the description of the QSAR, and 3) the application of 
the QSAR, also showing barriers for their use. Each thematic area was divided into a total of 13 main 
areas of concern with 49 assessment criteria covering all aspects of QSAR development, 
documentation and use. Two case studies were undertaken on different types of QSARs that 
demonstrated the applicability of the assessment criteria to identify potential weaknesses in the use 
of a QSAR for a specific purpose such that they may be addressed and mitigation strategies can be 
proposed, as well as enabling an informed decision on the adequacy of the model in the considered 
context. 
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Highlights  
 Uncertainties, variabilities and potential areas of bias and influences of QSARs are identified 
 The creation, description and application of QSARs is evaluated 
 13 types of uncertainty, variability, bias and influence of QSARs established  
 49 assessment criteria for QSARs are presented 
 Application of the assessment criteria will improve the uptake and use of QSARs 
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Introduction 
To understand the confidence that may be assigned to a prediction, there is a need to assess the 
underlying model and its suitability to make the prediction in question (Patterson and Whelan, 2017). 
With regard to the risk assessment of chemicals, many predictions can be made relating to hazard 
identification and potency as well as exposure assessment. For the prediction of toxicity and data gap 
filling in particular, the use of Quantitative Structure-Activity Relationship (QSAR) models is a well-
established technique (Cronin and Yoon, 2019). QSARs attempt to formalise the relationship between 
toxicity and chemical structure and properties such that a model may make a prediction, from 
structure, when data are missing. For the purposes of this paper, the term “QSAR” is taken in its 
broadest possible sense to include relationships between chemical structure and properties and 
toxicity that have been formalised into some type of model – this may range in complexity from 
structural alerts to machine learning, categoric definition of activity and continuous potency, and be 
based on any type of descriptor or property.  Being at the forefront of in silico toxicology for several 
decades, predictions from QSARs have found use in chemical regulations, such as for adaptation of 
information requirements in Annex XI of REACH (Spielmann et al., 2011). Despite this, in practice, 
QSARs are used mostly as supporting information or for screening purposes, although successfully 
integrated for example in the regulatory assessment practice of drug impurities, to predict 
mutagenicity according to the ICH M7 guidelines (ICH, 2017). However, for a wider uptake and 
successful regulatory use, an assessment and user-friendly communication of the confidence in the 
model and application is needed in order to enable the user or regulator to make an informed decision 
upon, and feel comfortable with, its use for the specific purpose in question (Worth, 2010).  
Whilst it is not the purpose of this paper to give a full review of QSARs, it is accepted that they stand 
at the juncture of biology, chemistry and statistics. QSARs for toxicity require (preferably high quality) 
data to be modelled with regard to appropriate descriptors, parameters and/ or properties of a set of 
chemicals. In theory and practice, any set of high-quality toxicity data for a coherent set of compounds 
is applicable. Descriptors for the various molecular properties are selected either empirically using 
mechanistic understanding, for example based on Molecular Initiating or Key Events of Adverse 
Outcome Pathways (AOPs) (Cronin and Richarz, 2018), or by statistical methods. Over five decades of 
progress has resulted in a multitude of descriptors of molecular structure and properties that include 
empirical, quantum chemical, or non-empirical parameters. Whilst empirical descriptors may be 
measured or estimated and include physico-chemical properties, non-empirical descriptors are 
typically structural features developed from the knowledge of 2D structure. Statistical methods to 
develop QSARs are typically either correlative or use pattern recognition approaches. The most 
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common correlative method is regression analysis whereas pattern recognition techniques are varied, 
often complex and maybe multi-dimensional and non-linear (Cronin and Madden, 2010). Overall, it 
can be surmised that the QSAR modeller has an enormous number of techniques and approaches to 
use resulting in a wide diversity of QSAR models. These approaches must be used appropriately to 
develop models that are robust and fit for purpose; where the purpose is to support regulatory 
assessment a means of assigning confidence to a prediction is required.  
The assignment of confidence to a prediction of toxicity requires the definition and assessment of the 
model and its suitability to make a prediction for a particular chemical (i.e., whether the chemical falls 
within the applicability domain) (Netzeva et al., 2005). The definition of a QSAR and discussions 
regarding the means of assessing their relative quality go back many decades and are well, and 
extensively, reviewed with regard to toxicity prediction elsewhere (cf. Cronin and Madden, 2010; 
Cronin et al., 2013). The assessment of the statistical fit of a QSAR and its overall performance are 
essential components to assess its quality and are ubiquitous in the science. As computational models, 
it was acknowledged early in the evolution of QSARs that statistical fit must be adequate for the 
intended purpose, but not too high as to imply over-fitting (Eriksson et al., 2003). Once computational 
techniques to perform statistical analysis became more widely available, more sophisticated statistical 
analyses were undertaken and there was a move from statistical fit to the assessment of predictivity 
of large external test sets, not necessarily considered in the model (Tropsha, 2010). Although an 
essential component of evaluating a QSAR, statistical veracity is only one part of the process to 
determine whether a prediction from a QSAR may be acceptable for a particular purpose.     
The use of QSARs to make prediction of toxicity to support legislation goes back at least to the 1980s 
(Cronin and Yoon, 2019; Worth, 2010). However, the modern paradigm of the regulatory use of QSARs 
for toxicity prediction was defined by the “Setubal Workshop” in 2002 (Jaworska et al., 2002; Cronin 
et al., 2003a, 2003b) with a particular focus on preparing for the requirements of the European Union’s 
then upcoming Registration, Evaluation, Authorisation and restriction of CHemicals (REACH) 
legislation. The Setubal Workshop sparked interest in assessing the limitations and practical 
considerations in using QSARs in a regulatory setting (e.g., Tong et al., 2005; Tunkel et al., 2005; Worth, 
2010), in particular, the issue of uncertainty (e.g., Sahlin et al., 2011; Ball et al., 2015). In order to 
assess and ensure the quality of a QSAR, aligned to the analysis of statistical performance, was the 
need for a better appreciation of the need for accurate representation of chemical structure, the 
intrinsic variability of the biological data and mechanistic basis on which a QSAR is based. This 
knowledge was cyrstallised into a set of six Principles for the “validation” of QSARs at the Setubal 
Workshop. These six principles were condensed to five when taken up as the OECD Principles for the 
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Validation of (Q)SARs for Regulatory Use (OECD, 2007; Worth, 2010). The Principles are often used as 
a framework to describe the content and performance of the model, for instance as applied using the 
QSAR Model Reporting Format (QMRF). In this context, the Principles, if applied appropriately by the 
model developer, may allow for formal validation of a model in terms of it being fit-for-purpose, or 
acceptable, in a regulatory context. The process of formal validation usually requires assessment 
against pre-defined validation criteria such that a non-expert in the field will have confidence in the 
use of the method. One of the shortcomings in the use of the Principles has been the failure to 
evaluate models fully against such criteria. As a result, to a certain extent they are a descriptive, rather 
than a diagnostic, means of defining and analysing a QSAR. Despite this, during the past 15 years the 
Principles have served the QSAR community (both users and developers) well, however they were not 
intended to be used for the breadth of QSAR approaches now available or be implemented with the 
context of 21st Century Toxicology – some examples of the types of uncertainties and how the science 
has developed are provided in Table 1. In addition, they do not necessarily allow or describe the ability 
to reproduce a QSAR or ensure its transparency (Patel et al., 2018; Piir et al., 2018), and have been 
applied in different ways and with different levels of detail by QSAR developers. As such, there is an 
opportunity to broaden the principles and incorporate newer thinking around toxicological problems. 
For instance, toxicology is moving to a more considered use of information with an emphasis on 
building weight of evidence (WoE) from individual lines of evidence. As part of this, there has been a 
growing emphasis on describing uncertainty(ies) associated with a model in an attempt to qualify, or 
even quantify, the areas where more information may be beneficial (Patterson and Whelan, 2017). In 
addition, there is a growing prominence of broader topics such as Good Computer Modelling Practice 
(GCMP) (Judson, 2009; Judson et al., 2015) as well as the understanding on how bias and variability 
affect into a model. In the broader context, the needs for all types of models in order to use them to 
make decisions have been defined with checklists presented to ensure model users and developers 
have considered the most significant factors for success (Calder et al., 2018). Thus, the assignment of 
the confidence in a model is dependent to a large extent on the identification of uncertainties, 
variability and biases and understanding, for QSARs, of how they may affect the prediction or the 
decision made based on the prediction, which may depend on the context considered. This 
information is necessary for the decision-maker to make an informed evaluation taking into account 
the potential limitations and for example an adequate risk-benefit-evaluation.  
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Table 1. A non-exhaustive list of the types of uncertainties in QSARs, with examples for the level of uncertainty, and where the scientific knowledge and 
methods have been extended since the publication of the OECD Principles (OECD, 2007). 
General aspects 
of the QSAR or 
its application 
Specific considerations 
and / or parts of the 
QSAR 
Examples of low / moderate / high uncertainty Extension of scientific knowledge since the 
publication of the OECD Principles 
    
Biological Data 
in the QSAR 
Quality of data  Low – OECD TG, GLP, adherence to Animal Research: Reporting of In 
Vivo Experiments (ARRIVE) guidelines etc.; multiple concordant 
values etc.  
Moderate – Accepted guideline, no GLP, or GLP but non-guideline; 
few or only one value 
High – Method not known or stated; little concordance between 
multiple values 
These issues were mostly considered in the 
original Principles 
Relevance of data for 
the endpoint of 
interest to its intended 
use 
Low – Endpoint measured (which will be the endpoint predicted by 
the model) is directly related to the (regulatory) endpoint of interest 
Moderate – Endpoint measured not the (regulatory) endpoint of 
interest, but closely related 
High – Endpoint measured related to an activity which might 
contribute to insights into the endpoint of interest 
More and different types of data are now 
utilised e.g. omics, high throughput etc. 
which may not have direct relevance to 
regulatory endpoint or apical effect but 
which may be useful for WoE in decision 
making 
Mechanisms of action Low – Strong evidence of underlying mechanism(s) of action and the 
model being demonstrably-related to the mechanism(s); for example, 
in terms of a Molecular Initiating Event or Key Event 
Moderate – Some, or partial, knowledge of mechanism and relevance 
to the QSAR 
High – No mechanistic hypothesis or relevance 
More mechanistic knowledge is collated, 
for example through Adverse Outcome 
Pathways (AOPs) than envisioned in the 
Principles 
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Descriptors in 
the QSAR 
Experimentally 
measured properties 
e.g. log P 
Low – OECD TG, GLP etc.; multiple concordant values etc.  
Moderate – Accepted guideline: no GLP, or GLP but non-guideline; 
few or only one value 
High – Method not known or stated; little concordance between 
multiple values 
These issues were mostly considered in the 
original Principles 
Calculated physico-
chemical properties 
Low – Reliable and reproducible descriptors; multiple reproducible 
values with low error 
Moderate – Two or more values with reasonable concordance 
High – Calculated descriptors not reproducible, little concordance 
between multiple values  
These issues were mostly considered in the 
original Principles 
Relevance of 
descriptors  
Low – Clear association to mechanism of action 
Moderate – Probable association to mechanism of action 
High – No association to mechanism of action 
Many more descriptors are currently 
applied including, for instance, molecular  
fingerprints etc. 
Statistical (or 
Other) Method 
Used in the 
QSAR 
Transparency and 
reproducibility of the  
model developed 
Low – Clearly defined and reproducible, i.e. fully transparent, model 
Moderate – Poor or no definition and / or transparency but model is 
reproducible 
High – Model is not defined, transparent nor reproducible 
There is a greater use of multivariate 
statistical methods, especially in machine 
learning, deep learning, artificial 
intelligence (AI) etc. since the publication of 
the original Principles 
Model performance  Low – Accurate model, good performance including low systematic 
error 
Moderate – Poor model performance or accuracy 
High – Accuracy/performance not known 
More is known about the assessment of 
model performance since the publication 
of the original Principles e.g. different types 
of metrics, need to perform external 
validation etc. 
Applicability of 
the QSAR 
Applicability domain Low – Relevant applicability domain clearly defined 
Moderate – Applicability domain not clearly defined or ambiguous 
High – Applicability domain not known 
More is known about describing 
applicability domains and the different 
aspect that may be required, e.g. 
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structural, properties, metabolism etc., 
since the original Principles 
Relevance of the QSAR 
to the prediction or 
assessment goal, i.e. 
how much uncertainty 
does the QSAR bring to 
the WoE, IATA, Defined 
Approach (DA) etc.  
Low – The QSAR is well-used and considered unambiguous; related 
directly to the endpoint being predicted 
Moderate – The QSAR is novel and /or poorly transparent; or poorly, 
or not, related to the endpoint being predicted 
High – The QSAR is not transparent; poorly or not related to the 
endpoint being predicted; contradictory to other evidence in a WoE, 
IATA or DA 
The widespread use of QSARs as part of 
strategies including WoE, IATA and DA, as 
opposed to being standalone, was not 
foreseen in the original Principles 
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There are various definitions of uncertainty with regard to toxicological assessment, it is beyond the 
scope or possibility of this paper to review all of these, or indeed to standardise them, but some key 
definitions include the following. The World Health Organisation International Programme on 
Chemical Safety (WHO IPCS) gave a general definition of uncertainty as “imperfect knowledge 
concerning the present or future state of an organism, system, or (sub)population under consideration” 
(WHO IPCS, 2004). Relevant to this paper, the WHO IPCS (2004) definition was refined specifically to 
hazard characterisation "as lack of knowledge regarding the “true” value of a quantity, lack of 
knowledge regarding which of several alternative model representations best describes a system of 
interest, or lack of knowledge regarding which probability distribution function and its specification 
should represent a quantity of interest” (WHO IPCS 2017). ECHA (2012) builds on the WHO IPCS 
definition stating “Uncertainty can be caused by limitations in knowledge (e.g. limited availability of 
empirical information), as well as biases or imperfections in the instruments, models or techniques 
used. An example is an emission estimate that is based on a reasonable-worst case assumption.”. 
Whilst these (and other) formal definitions are not discounted, this paper has preferentially 
considered the possibly broader terminology proposed by EFSA (2018a) which defined uncertainty as 
“all types of limitations in available knowledge that affect the range and probability of possible 
answers to an assessment question” (EFSA, 2018a). The EFSA Guidance is based around identifying, 
assessing, describing and, in some cases, quantifying uncertainty. There have been a variety of 
approaches that have attempted to define uncertainty in toxicological QSAR including those based on 
epistemological and other analyses (Vallverdu, 2012) and various statistical approaches (e.g., Sahlin 
2013; Sahlin et al., 2013; Sahlin, 2015). Aligned to the concept of uncertainty is its quantification and 
the fact that increasingly robust quantitative uncertainty analysis frameworks have been developed 
which have provided a unified framework for hazard characterisation (WHO IPCS, 2017; Chiu and Slob 
(2015). It is acknowledged that this study does not itself attempt full quantification, but that there is 
a growing need for it to enable decisions regarding the acceptability of a prediction to be made. Whilst 
the areas of uncertainties relating to read-across have been identified (Schultz et al., 2019), and a 
checklist of elements to consider as part of an expert review of QSARs has been developed (Myatt et 
al 2018), as yet there has been no coherent mapping or definition of uncertainty with regard to QSAR 
models.  
As with uncertainty, there are various definitions of variability (cf. ECHA, 2012; EFSA, 2018b; NRC, 
2009; US EPA, 2001 amongst many others). Again, this paper does not propose a formal definition of 
variability but has taken it to refer, in a broad sense, to an actual variation or heterogeneity that can 
be measured or assessed in some manner and may possibly be reduced with further information ─ 
i.e., in common with EFSA (2018b). This paper also considered areas of bias and influence. Bias can be 
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defined as the possibility of introducing systematic error in the results (e.g., for the purposes of this 
study, a prediction) resulting from methodological criteria (Higgins and Green, 2008) with a number 
of approaches of measuring it (cf. Hooijmans et al., 2014; Krauth et al., 2014). For this study influence 
implies any aspect (particularly not relating the algorithm or data behind a model) that made a 
particular model preferable to another e.g. a cognitive bias (cf. Arnott, 2006), thus meaning that other 
predictions could have been made which may have had higher confidence. In the context of bias and 
influence in toxicological QSAR, these concepts have been taken to mean any direct or indirect aspects 
and/or motivations relating to the development, use or interpretation of a model that could be subject 
to change in a different context or situation – in other words, areas where human decisions have 
affected the model or use of a model.   
The assessment of uncertainties, variabilities, biases and areas of influence of QSARs will undoubtedly 
allow for a more didactic and context dependent evaluation of their use for toxicity prediction. Overall, 
this would allow to increase confidence in QSAR models and, as a consequence, further their uptake 
and use in practice. It is not the purpose of the proposed scheme in this paper to consider any 
uncertainties, variabilities, biases or influences together or to combine in some way to provide an 
overall score – this would require a more mathematical approach. However, it is intended that a 
review of a QSAR model according to the assessment criteria defined will allow a user of a model and 
a user of a prediction of a model to identify any aspect where confidence may be lacking and make an 
assessment as to whether this is acceptable for the decision to be made (e.g., is the level of confidence 
sufficient to make a specific regulatory decision).  
The aim, therefore, of this paper was to identify and describe the areas of uncertainty, variability, bias 
and influence with regard to the prediction of toxicity by QSARs, namely the issues that affect the 
development, description and utilisation of (Q)SARs. A list of criteria was compiled for each of these 
three areas that can be applied systematically in order to identify key uncertainties with a QSAR 
model. These assessment criteria were applied to two published QSAR studies in order to illustrate 
their utility to identify areas of high uncertainty, variability, bias and influence, allowing the confidence 
in the model to be evaluated and for mitigation strategies to be formulated. 
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Methods 
Identification of Assessment Criteria for the Uncertainties, Variabilities and Areas of Potential Bias and 
Influence in a QSAR for Toxicity Prediction 
An expert review was undertaken of various types of QSAR analyses for the prediction of toxicity. The 
specific QSARs are not listed here but drew on the experience of the authors. The review included 
published and unpublished QSARs, as well as free-to-use and with-payment computational products. 
From the review based on the experience of the authors, types of uncertainties, variabilities, bias and 
influences on the development and use of a QSAR for toxicity prediction were compiled and organised 
logically into assessment criteria. The assessment criteria were intended to be objective, although it 
is noted that subjectivity will inevitably be part of the evaluation of a model when the criteria are 
applied. Whilst the classifications are only indicative and for regulatory use would need to be placed 
in the context of decision and protection goal, Table 2 provides generic definitions of what is termed 
low, moderate and high uncertainty. These are definitions for use in this study and it is acknowledged 
that specific definitions may be available in guidance documents (cf. EFSA (2018b), WHO IPCS (2017)) 
and relevant legislation. 
 
Table 2. Generic definitions and putative relevance to regulatory decision making of the terms low, 
moderate and high uncertainty of QSARs for toxicity prediction as used in this study. 
 
Uncertainty Generic Definition Relevance to Regulatory Decision Making 
   
Low The evidence and / or hypothesis on 
which a decision or result is based 
indicates it is highly probable that the 
finding is correct 
High confidence in QSAR models and predictions; they 
may support decisions relating to risk assessment, 
classification and labelling (C&L) and prioritisation 
Moderate The evidence and / or hypothesis on 
which a decision or result is based 
indicates it is probable that the finding 
is correct 
Moderate confidence in QSAR models and 
predictions; they may probably be used to support 
decisions relating to C&L and prioritisation 
High There is no or little evidence and / or 
hypothesis that the result is correct 
Low confidence in QSAR models and predictions; they 
may be used to inform prioritisation as part of a 
weight of evidence  
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Application of the Uncertainty, Variability, Bias and Areas of Influence Assessment Criteria to Case 
Studies 
The compiled assessment criteria for uncertainty, variability, bias and influences of a QSAR were 
designed to allow for the evaluation of QSARs. To illustrate their application, the assessment criteria 
were applied to two case studies as examples using a simplistic scale of high, moderate and low 
uncertainty, variability or bias and area of influence for each criterion. The case studies, two of the 
authors’ studies, were chosen to represent different modelling approaches to address different 
endpoints with the intention of demonstrating how applications of the identified sources of 
uncertainties, variabilities, biases and areas of influence in QSARs may emerge. 
Case Study 1. A regression-based QSAR utilising the logarithm of the octanol-water partition 
coefficient (log P) to describe the inhibition of growth (IGC50) of compounds considered to be acting 
by the non-polar narcosis mechanism of action to the ciliated protozoan Tetrahymena pyriformis 
(Ellison et al., 2008). The QSAR is as follows: 
Log 1/IGC50 = 0.78 log P – 2.01 
Case Study 2. An in silico workflow that is based firstly on a variety of predicted physico-chemical 
properties and descriptors and secondly on molecular fragments associated with toxicity which had 
been coded in SMARTS strings with the aim of identifying compounds that have the capacity to bind 
to nuclear receptors associated with hepatic steatosis (Mellor et al., 2016). 
The findings of the application of assessment criteria were summarised using expert judgement. This 
applied defined examples of the scoring system for low, medium or high uncertainty, variability, bias 
or influence. Possible strategies to mitigate areas of high uncertainty, variability, bias or influence 
were proposed on a pragmatic basis that could be achieved with limited further testing or resources. 
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Results and Discussion 
Toxicology is a science based on measurement, description and analysis of experimental findings. As 
a scientific discipline it inevitably relies on interpretation of evidence to make a decision. With the 
paucity of resources available for toxicological assessment, much has been placed into maximising the 
possible information that may be obtained without recourse to animal testing and / or by utilising 
existing data. Part of this process of maximising the value and utility of data has been to assign 
confidence to information by understanding the uncertainties within toxicological results, with a view 
to minimising the knowledge required in a cost- and resource-efficient manner (Patterson and 
Whelan, 2017). In silico models contribute to toxicological knowledge through chemistry- and 
property-based predictions (Cronin and Madden, 2010) increasing the understanding of complex 
causal interrelations. These form a special case in toxicology as an understanding of their uncertainties 
means that the predictions can be improved and may be considered to have greater confidence. For 
instance, the inclusion of New Approach Methodology (NAM) data has been shown to reduce 
uncertainty in read-across (Schultz and Cronin, 2017) and a similar approach could be envisioned for 
QSARs. Whilst the uncertainties in read-across (Schultz et al., 2019) and for mathematical modelling 
in Next Generation Risk Assessment (Gosling, 2019) have been defined and described this is not the 
case for QSARs specifically. In addition, ECHA (2017) has defined the Read-Across Assessment 
Framework (RAAF) as a means of evaluating a read-across argument for toxicity prediction based, in 
part at least, on an understanding of the quality of the justification and data and assessment of 
similarity. Whilst a one-to-one read-across (i.e. an analogue approach) can be considered a unique 
situation, the RAAF does also allow for read-across from many chemicals. When a reasonable number 
of chemicals are included in a category for read-across, especially for a quantitative endpoint, the 
distinction between read-across and QSAR becomes blurred. As such, this investigation has developed 
a comprehensive set of assessment criteria that describe uncertainties and potential areas of 
variability, bias and areas of influence in QSARs and demonstrated its applicability to published QSARs, 
whilst being mindful that these criteria could find use, in certain circumstances, for read-across when 
trend analysis or QSAR is applied. It is emphasised that the assessment criteria go beyond 
uncertainties to areas that influence the development and use of a QSAR (e.g. motivation, cost, etc.) 
but which may assist in the evaluation of quality, or practical applicability, of a model. 
Following an expert review and evaluation of numerous in silico approaches, uncertainties, as well as 
areas of variability, bias and influence, associated with QSARs have been assigned to one of three 
“thematic” areas, namely that from the creation of the model, the description of the model and the 
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application of the model. Specifically, the three main thematic areas relating to uncertainties, 
variabilities and areas of potential bias and influence in a QSAR were: 
1. Model Creation: the information on which the QSAR is based including the quality, 
consistency, variability, reporting and reliability of the toxicological data, chemical structures 
and properties / descriptors as well as the development and nature of the algorithm that 
forms the basis of the QSAR. The completeness of the data set is assessed as is how 
appropriate the modelling approach is. 
2. Description: the reporting of the model, i.e. transparency, in terms of the type of an 
(unambiguous) algorithm, its performance and definition of applicability domains and 
mechanistic and toxicokinetic relevance. 
3. Application: aspects of the usability, or barriers to it, of the model are considered, including 
the actual reproducibility based on the documentation; different influences on the choice of 
using a particular model; as well as the relevance and adequacy of a model for a particular 
purpose (if known), in particular for possible regulatory applications. 
The assessment criteria for the three thematic areas are described in detail in Tables 3-5 respectively 
along with examples, comments and reference to whether the information may be retrieved from the 
QMRF. The first and second thematic areas (i.e., Model Creation (Table 3) and Description (Table 4)) 
draw heavily from, and extend, the OECD Principles for the Validation of QSARs. The third thematic 
area, Application (Table 5), goes beyond what is considered in the OECD Principles to draw on 
experience of the practical usage of a model – it is acknowledged at the outset that many of the issues 
considered here are not uncertainties but potential areas of variability, bias as well as influences on 
and barriers to the use of QSARs. In Tables 3 – 5 each criterion is classified as being an uncertainty, 
variability, bias or influence, with some criteria having two such classifications. These classifications of 
the criteria are broad and are unlikely to be definitive at this time. However, such criteria could form 
the foundation of formal validation, guiding an assessor through the assessment and documentation 
of the different issues described. 
Table 3 summarises a total of 20 potential assessment criteria, in terms of areas of concern (i.e., 
uncertainties, variability, bias) that are associated with the raw data used to develop a QSAR and the 
modelling technique. The assessment criteria are sub-divided according the type of data and their role 
in the development of a QSAR. The issues associated with the accuracy of chemical structures are 
defined in Section 1.1 with an overriding requirement for correct definitive structures (Young et al., 
2008; Ball et al., 2016). Seven areas of uncertainty, variability or bias have been identified for the 
biological / toxicological data on which a QSAR is developed (Section 1.2). Key amongst these are the 
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intrinsic quality and error associated with the data – well-established and newer schemes to evaluate 
such criteria are available (Klimisch, 1997; Przybylak et al., 2012; Moermond et al., 2016; Molander et 
al., 2015, Myatt et al, 2018; NTP, 2015), as well as the consistency and comparability of the data 
compiled to a data set. Also noted is the use of nominal or measured concentrations – with the 
realisation that whilst measured internal concentrations are preferred, the majority of historical 
toxicological data for modelling are based on nominal concentrations (Partosch et al., 2015). Five 
uncertainties relating to the molecular descriptors or properties on which a model is derived are 
accounted for in Section 1.3, the intention here is to encourage correct use and documentation of 
software, or description of experimental measurements, rather than being prescriptive of the type of 
descriptor. Sections 1.4 and 1.5 account for the uncertainties or potential bias that may be related to 
issues of the completeness and content of the data set and appropriateness of the modelling 
approach. 
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Table 3. Description of the assessment criteria relating to uncertainties, variability and bias that may be associated with the creation of QSAR models.  
IID 
Number 
Assessment 
Criteria for 
Individual Areas 
of Uncertainty, 
Variability or Bias 
Example of Low 
Uncertainty, 
Variability or Bias 
Example of 
Moderate 
Uncertainty, 
Variability or Bias  
Example of High 
Uncertainty, 
Variability or 
Bias 
Comment or Other 
Information 
Type of Criterion Information 
Potentially 
Retrievable 
from the 
QMRF 
        
1.1 Definition of Chemical Structures 
        
1.1a Accuracy of 
chemical 
structures 
Structures 
unambiguously 
defined including 
any isomerism such 
as tautomerism and 
stereoisomerism 
Structures well-
defined with small 
numbers of 
ambiguities  
Structures not 
defined 
Definitive chemical 
structures are required 
including any possible 
tautomerism, 
stereochemistry etc.  
Uncertainty about the active 
molecule if exact structure not 
known 
 
Variability of structures due to 
different forms of isomerism 
(leading to uncertainty about 
which structures and related 
properties/activities are 
included in the data for 
modelling and possible impact 
on the model) 
Yes 
1.1b Assessment of 
significant 
impurities or 
mixtures  
Impurities / 
mixtures defined 
and stated 
Major impurities / 
and components in 
mixtures defined and 
stated; only low 
concentration 
components omitted 
Impurities / 
mixtures not 
stated 
 Uncertainty about the active 
molecule(s), if not known which 
components present at the 
time of measurement 
 
Variability of composition for 
example for nanomaterials 
Yes 
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(inherent distribution of size 
etc.)  
        
1.2 Biological Data 
        
1.2a Quality of 
individual studies 
in the data set 
Standard test, OECD 
Test Guideline (TG), 
performed to e.g. 
Good Laboratory 
Practice (GLP) 
standard, adherence 
to ARRIVE 
Guidelines 
A well-recognised 
and described test 
but not necessarily 
performed to GLP 
and/or OECD Test 
Guidelines 
Quality  
not known / 
determinable or 
a not recognised 
non-standard 
test protocol 
applied 
Evaluation of data quality 
may require analysis of the 
original study reports / 
publication. Criteria such 
as Klimisch (1997) or 
SciRAP (Molander et al., 
2015) scores, or the 
SYRCLE risk of bias tool for 
animal studies (Hooijmans 
et al., 2014) may be useful. 
It is acknowledged that a 
non-standard/ non-
guideline test may be high 
quality. 
Uncertainty about the model if 
underlying data of questionable 
quality 
 
Bias relating to systematic 
errors in the studies leading to 
erroneous data 
No 
1.2b Consistency of 
the data set 
including 
comparability of 
data 
Consistent set in 
terms of assay, 
same laboratories 
Minor 
inconsistencies in the 
data set, e.g., in test 
protocols or testing 
laboratories 
Varied test 
guidelines / 
sources of data 
Do the individual data 
points form a consistent 
set of data from which to 
develop a model in terms 
of the assays, 
measurement etc.  
Uncertainty about quality, i.e. 
consistency, of the underlying 
data set and its impact on the 
model 
No 
1.2c Checking of 
toxicological data 
Source data / study 
reports checked 
against the original 
study reports 
Most data checked, 
or in the case of a 
large data set a 
random sample 
checked and verified 
No checking Have the data been 
checked e.g. with 
reference to the source of 
the data 
Uncertainty that may be 
introduced due to the 
quality/correctness of the 
underlying data set for the 
model 
No 
1.2d Error associated 
with biological 
data 
Error is known and 
stated and within 
what would be 
Error is not known 
for some compounds 
Unknown error Is an estimate of the error 
associated with biological 
data e.g. the measurement 
Uncertainty about 
measurement errors and thus 
No 
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normally associated 
with the test 
in the data set or 
very significant 
error and intrinsic 
variability of the test/ 
measured property 
provided? The 
requirement for 
knowledge of error is so 
that the model is not 
overfitted. Naturally 
modelling with data with 
low error is preferred. 
quality of the data set and its 
impact on modelling 
 
Variability relating to the 
property to be measured which 
may vary among individuals 
1.2e (if required) 
Units of 
concentration 
known, stated 
and appropriate 
for use 
Appropriate units 
stated 
Units stated but they 
may not be wholly 
appropriate 
Not known or 
not stated 
For measures of potency, 
typically molar units are 
required  
Uncertainty about the model if 
based on not appropriate 
values  
Yes 
1.2f (If appropriate) 
Use of nominal 
or measured 
concentrations  
Measured 
experimental 
concentrations used 
taking account of 
degradation, uptake 
etc. over time 
course of the test 
Experimental 
concentrations used, 
although without 
reference to time 
course (e.g., a single 
measurement) 
Nominal 
concentrations 
used 
 Uncertainty about adequate 
data used for modelling 
No 
1.2g Taking into 
account of the 
internal 
exposure 
Internal exposure 
known 
Internal exposure 
estimated 
Internal 
exposure not 
known 
The internal exposure is 
the actual concentration at 
the tissue or in the cell 
Uncertainty about the actual 
concentration at the relevant 
site and impact on the data and 
modelling 
No 
        
1.3 Measurement and / or Estimation of Physico-Chemical Properties and Structural Descriptors 
        
1.3a Measurement of 
physico-chemical 
Measurement by 
appropriate OECD 
TG / according to 
A well-recognised 
and described test 
but not necessarily 
Experimental 
procedure not 
known, little 
 Uncertainty relates to 
underlying data quality and 
impact on the model 
Yes 
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properties and 
descriptors 
GLP, multiple 
concordant values 
etc. 
performed to GLP 
and/or OECD Test 
Guidelines 
concordance 
between 
multiple values 
 
Variability is anticipated for 
measured properties, such as, 
for example, for nanomaterials 
1.3b Calculation of 
properties and 2-
D descriptors 
Reliable and 
reproducible 
descriptors, multiple 
reproducible values 
with low error  
Two or more values 
with reasonable 
concordance  
Calculated 
descriptors not 
reproducible, 
little 
concordance 
between 
multiple values  
 Uncertainty about impact of 
possible low descriptor quality 
on the model 
Yes 
1.3c Calculation of 3-
D descriptors, if 
utilised 
Full structure 
optimisation and 
conformational 
analysis 
Structure 
optimisation 
performed without 
conformational 
analysis 
No optimisation 
of chemical 
structure 
 Uncertainty within the model if 
3-D structure is not fully 
optimised 
 
Variability relating to variations 
in 3-D conformations which 
might have an impact on 
descriptors used for modelling 
Yes 
1.3d Software utilised 
for descriptor 
calculation 
Full details of 
software and any 
options / non-
default  
Software known, but 
use (options/ 
parameters) not fully 
described  
Software not 
described 
Full version number, 
parameters used etc. of 
software reported 
Uncertainty about the quality 
of the descriptors and thus of 
the model 
Yes 
1.3e Definition of 
molecular 
fragments 
Correct fragments 
used, definition of 
the fragment and its 
domain defined 
Fragments used, but 
significance unknown 
Non-defined 
fragments 
 Uncertainty about the quality 
of the molecular fragments and 
impact on model 
Yes 
        
1.4 Compilation of the Data Set for QSAR Modelling 
        
1.4a Data set is 
complete  
No data gaps Minor number of 
missing data (e.g., 
when experimental 
Data gaps 
present 
All data (e.g., structure, 
toxicological and 
physicochemical 
Uncertainty about the model if 
developed based on 
incomplete dataset  
Yes 
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properties are 
missing or 
supplemented by 
calculated values) 
properties) should be 
available for all chemicals 
used for modelling 
1.4b Data set has 
appropriate 
variation in 
potency 
(quantitative) or 
balance of 
actives vs 
inactives 
(qualitative) 
Good variation in 
potency (e.g., 
several log units) or 
balanced actives / 
inactives 
Moderate range of 
potency or balance 
of actives / inactives 
Limited range of 
potency or 
imbalanced data 
set 
 Uncertainty about the model 
based on unbalanced dataset 
 
Bias relating to the selection of 
the data set relating to the 
endpoint, application and 
intended use, and experience 
of the model developer 
Yes 
1.4c Selection of 
training set data 
for modelling 
Data selection 
reported to be 
without bias, 
removal of outliers 
has been explained. 
This may include 
mechanistic 
selection of 
compounds or 
according to specific 
chemistries. 
Data selection 
assumed to be 
without bias 
(although not 
reported). No outlier 
removal apparent or 
reported 
Unknown or 
unexplained bias 
in the selection 
of data to model  
QSAR models are seldom 
developed with all 
available data; selection 
criteria should be 
acknowledged 
Uncertainty about the model 
(and possible bias) if data 
selection procedure not known 
and different compilations of 
data sets are possible 
 
Bias from the model developer 
who may have applied implicit 
or existing/perceived 
knowledge to the selection of 
the training set 
Yes 
1.4d Homogeneity of 
the chemical 
space of the 
training and test 
sets (related to 
Criterion 2.3a) 
Chemicals are 
heterogeneous 
across chemical 
space (and e.g. 
descriptor space, 
mechanistic space) 
Chemicals are 
moderately well 
distributed across 
chemical space with 
some areas of high 
density and some 
areas of low density 
Chemicals are 
poorly 
distributed 
across chemical 
space or the 
distribution is 
not known 
Heterogeneity and 
distribution can be 
demonstrated by for 
example, visualisation of 
density (cf. Jaworska et al., 
2005; Hanser et al., 2016) 
Uncertainty relating to the 
distribution across chemical 
space of the underlying data 
sets which may skew the model 
and give false predictions for 
the target chemical 
 
Bias from the chemical space of 
the data set which might be 
No 
23 
 
influenced by the experience of 
the model developer or the 
model’s intended use or 
application 
1.4e Suitable split into 
training and test 
sets, sets defined 
and utilised 
As required, 
appropriate training 
and test sets 
Only small test sets 
utilised, lack of 
resampling of data 
etc.  
Split into 
training and 
tests lacking 
 Uncertainty about appropriate 
building and use of the training 
and test sets which may impact 
on the model 
Yes 
        
1.5 Modelling Approach 
        
1.5a How appropriate 
is the modelling 
approach for the 
endpoint and to 
deal with the 
complexity / 
non-linearity of 
the data 
Appropriate 
modelling approach 
for the endpoint 
Modelling approach 
likely, but unproven, 
to be appropriate for 
the endpoint 
Approach likely 
to be too 
complex or 
simplistic 
This requires a pragmatic 
and subjective assessment, 
e.g. a data set based on 
one mechanism with a 
single overriding 
descriptor can be afforded 
a simpler modelling 
approach as to one that is 
more complex 
Uncertainty  about the model if 
the modelling approach chosen 
not appropriate  
 
Bias from different approaches 
to modelling which may result 
from personal knowledge, 
experience or prejudice 
No 
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Table 4 describes 13 assessment criteria for areas of concern (i.e., uncertainties) associated with the 
documentation of the model. This is closest to the QMRF which describes many of the features 
accounted for in Table 4 (Worth, 2010). Indeed, it is anticipated that a QMRF could be a valuable 
source of reference to address these criteria. As well as criteria closely aligned to the OECD Principles 
for the Validation of QSARs, i.e. transparent description of the model, performance, applicability 
domain, and mechanistic relevance are summarised in Sections 2.1-2.4, Section 2.5 extends the 
analysis to include explicit consideration of toxicokinetics (which were not envisaged in the original 
Principles).  
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Table 4. Description of the assessment criteria relating to uncertainties that may be associated with the description of QSAR models. 
 
ID Number Assessment Criteria 
for Individual Areas 
of Uncertainty 
Example of 
Low 
Uncertainty  
Example of 
Moderate 
Uncertainty  
Example of 
High 
Uncertainty  
Comment or 
Other 
Information 
Type of Criterion Information 
Potentially 
Retrievable 
from the 
QMRF 
        
2.1 Description of Model 
        
2.1a Definition and 
description of model 
(related to Criterion 
3.1a) 
Model fully 
defined 
A small number of 
aspects of the 
model non-defined 
or ambiguous 
Model non-
defined or 
ambiguous 
All terms e.g. 
descriptors, 
statistical 
values, 
algorithms 
should be 
defined. The 
QMRF is a 
possible 
reporting 
format 
Uncertainty about 
model if not 
completely defined 
or described: model 
cannot be retraced 
and evaluated 
Yes 
2.1.b Underlying data set is 
fully described 
All data are 
provided and 
described 
The data set is 
described/provided 
partially (not all 
properties or 
structures are fully 
described)  
Data set is 
neither 
provided nor 
described 
All data (e.g., 
structure, 
toxicological 
and physico-
chemical 
properties) 
should be 
reported 
Uncertainty about 
model if underlying 
data cannot be 
retraced or verified 
Yes 
26 
 
2.1c Transparency of the 
model 
Model is 
transparent in 
terms of the 
algorithm and 
can be 
interpreted 
and 
reproduced 
Model is defined 
providing some 
aspect of 
transparency, but 
may not be 
reproducible. The 
algorithms of, e.g. 
neural networks, 
may be difficult to 
interpret even if 
transparent. 
Non-
transparent 
model 
A transparent 
model can be 
fully 
understood, 
reproduced and 
coded by 
another user 
Uncertainty about 
the model if not 
retraceable/ 
reproducible, cannot 
be evaluated  
Yes 
        
2.2 Statistical Performance 
        
2.2a Statement of 
statistical fit, 
performance and 
predictivity  
Full description 
of model 
performance 
Some key 
measures of model 
performance 
missing 
Limited or no 
description of 
model 
performance 
The use of 
appropriate 
validation 
methods and / 
or external test 
sets should be 
demonstrated, 
different 
metrics may be 
required for 
different models 
Uncertainty about 
model accuracy and 
quality of the 
prediction if no 
information about 
the model 
performance 
Yes 
2.2b Interpretation of 
statistical fit etc with 
respect to biological 
measurement error 
and variability (see 
Criterion 1.2d)  
Statistical 
performance is 
significant but 
not overfitted 
Statistical 
performance 
moderate or 
possibly overfitted 
No statistical 
significance or 
overfitted as 
compared to 
experimental 
error 
 Uncertainty about 
the model if 
performance is not 
adequate or 
overfitted 
No 
        
2.3 Applicability Domains 
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2.3a Chemical, structural 
and descriptor 
applicability domain 
of model 
Fully defined in 
terms of 
relevant 
physico-
chemical 
properties and 
structural 
descriptors 
Domain defined 
but not in terms of 
all key aspects 
Not defined This can be 
defined by many 
methods but 
should be 
appropriate for 
the model 
Uncertainty about 
the applicability of 
the model for the 
target chemical 
Yes 
2.3b Mechanistic 
applicability domain 
of model 
Fully defined in 
terms of 
relevant 
mechanism(s) 
of action 
Partial definition of 
mechanistic 
domain 
Not defined Reference may 
be made here to 
relevant AOPs 
Uncertainty about 
the applicability of 
the model for the  
target chemical  
Yes 
2.3c Biological 
applicability domain 
of model 
Fully defined 
including 
possible 
metabolism 
Partial definition of 
biological domain/ 
metabolic domain 
Not defined This could refer 
to, for instance, 
consistent NAM 
data and 
profiles for the 
data set, e.g. 
from ToxCast  
Uncertainty about 
the applicability of 
the model for the 
target chemical 
Yes 
        
2.4 Mechanistic Relevance and Interpretability 
        
2.4a Mechanistic 
justification 
Causative 
definition of 
mechanism of 
action or 
reference to 
AOP 
Putative definition 
of mechanism of 
action or reference 
to AOP 
No 
mechanistic 
basis 
If multiple 
mechanisms are 
present in the 
dataset, this 
should be 
acknowledged 
and, where 
possible, 
defined 
Uncertainty about 
the model due to 
unknown 
mechanistic 
justification 
Yes 
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2.4b Presence / availability 
of other and 
supporting 
information to 
support mechanistic 
interpretation or 
validity 
Use of 
supporting 
NAMs, other 
data or other 
evidence 
relating to 
mechanistic 
basis 
Partial supporting 
data e.g. for 
limited proportion 
of the data set 
No supporting 
information 
This would 
normally form 
part of the 
accompanying 
justification and 
documentation 
and may, for 
instance, 
confirm 
mechanism of 
action 
Uncertainty about 
the model if 
insufficient evidence 
provided  
No 
2.4c Relevance of 
descriptors to 
mechanism of action 
/ AOP 
Descriptors or 
properties 
clearly and 
causally 
related to 
mechanism 
Partial or 
correlated 
relationship to 
mechanism 
No 
mechanistic 
basis of 
descriptors  
 Uncertainty about 
model if relevance of 
descriptors used for 
modelling not known 
or interpretable  
Yes 
        
2.5 Adequate coverage of Absorption, Distribution, Metabolism and Excretion (ADME) effects 
        
2.5a Metabolism and / or 
effect of significant 
metabolites have 
been considered 
Role of 
metabolism in 
eliciting the 
toxicity is 
established 
Metabolism is 
assumed but 
without 
experimental 
evidence  
No reference 
to metabolism 
This could 
include whether 
the test system 
is metabolically 
competent  
Uncertainty about 
possible impact of 
metabolism or 
metabolites on the 
model and predicted 
effect 
No 
2.5b Toxicokinetics have 
been addressed in 
the model 
Model relates 
to toxicokinetic 
considerations 
that affect 
toxicity or 
potency 
Model only 
partially relates to 
toxicokinetics 
No reference 
to 
toxicokinetics 
 Uncertainty about 
the role and possible 
impact of 
toxicokinetics on the 
model 
No 
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The criteria relevant to the practical application and use of a QSAR, in particular for possible regulatory 
uses, are addressed in Table 5. The 16 assessment criteria in Table 5 continue to move away from 
uncertainties, variability and bias to provide a greater understanding of areas of bias, influence and 
the appropriateness of a QSAR to address a specific problem as well as potential barriers to their use. 
Section 3.1 considers whether a model is sufficiently documented and the documentation allows the 
model to be reproduced for the required purpose. Such considerations have been shown to be very 
important in terms of use of a model and reproducibility not always given even when QMRFs were 
available (Patel et al., 2018; Piir et al., 2018). Section 3.2 considers the model from the user’s 
perspective and requires consideration of the accessibility and utility – such as in terms of user-
friendliness or costs – of a particular QSAR. In addition, the sustainability of a QSAR is addressed, as 
this is seen as a significant factor in the use of a model (Cronin et al., 2019). These criteria go beyond 
the model itself into understanding where it is practically usable and possible related 
concerns/barriers, e.g. intellectual property or ethical concerns. Finally, but most importantly 
especially for regulatory applications, the relevance and adequacy of a QSAR to make a prediction for 
a specific effect for the endpoint considered and the specific hazard/risk assessment context is 
addressed in Section 3.3. 
Many of the assessment criteria in Table 5 move away from what is traditionally considered in the 
evaluation of a QSAR, however they relate to the applicability of a particular model to provide data 
for one or more problem(s). As with any of the assessment criteria, the assessor may omit specific 
criteria should they be deemed not relevant or out of scope for the model or purpose. Assessment 
criteria 3.3d and 3.3e (human health vs environmental effects) are likely to be mutually exclusive for 
most use case scenarios. In addition, there is consideration of aspects of inherent (and cognitive) bias 
and hence this is moving away from classic areas of uncertainty to other areas that should be 
considered to gain a full understanding of where bias and other areas of influence could enter in a 
model. For instance, these may be used to identify issues such as models being deliberately developed 
to be sensitive or specific – both of which are legitimate modelling approaches but require to be 
identified for use. Assessment Criteria 3.2b and 3.2d move away from the model itself into issues that 
may bias model development or application e.g. a model may be biased towards certain chemistries 
or solving a particular problem. Identification of areas of bias does not preclude any use of a model 
but it allows the user to understand how it may be used and potential strengths and weaknesses.  
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Table 5. Description of the assessment criteria relating to uncertainties, and areas of bias and influence that may be associated with the application of QSAR 
models.  
 
ID 
Number 
Assessment 
Criteria for 
Individual Areas of 
Uncertainty, Bias 
and Influence 
Example of Low 
Uncertainty, Bias and 
Influence 
Example of 
Moderate 
Uncertainty, Bias 
and Influence 
Example of High 
Uncertainty, 
Bias and 
Influence 
Comment or 
Other 
Information 
Type of Criterion Information 
Potentially 
Retrievable 
from the 
QMRF 
        
3.1 Documentation and Reproducibility 
        
3.1a Reproducibility of 
the model or QSAR 
(related to 
Criterion 2.1a) 
 
Full documentation, 
availability of data 
and details of 
software do allow to 
repeat the QSAR de 
novo 
Some aspects of the 
model, software or 
data are not 
available, meaning 
there is difficulty in 
reproducing the 
model  
QSAR cannot be 
reproduced 
To determine 
reproducibility, 
the model is 
assumed to be 
transparent 
(see Criterion 
2.1c) 
Uncertainty about 
the model if it 
cannot be 
reproduced 
No  
3.1.b 
 
Reproducibility of 
the QSAR 
prediction 
Application of the 
model to the same 
chemical always gives 
the same prediction 
result (using the same 
descriptors) 
Model does not give 
reproducible 
predictions without 
careful control of 
descriptors 
Model does not 
give 
reproducible 
predictions 
To obtain 
reproducible 
predictions, all 
parameters 
(descriptors) 
need to be 
available and 
controllable 
Uncertainty will be 
increased if 
predictions are not 
reproducible 
No 
        
3.2 Usability 
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3.2a Implementation of 
the model 
Fully implemented 
into software 
Model has the 
potential to be 
implemented but 
this has not been 
undertaken 
No 
implementation 
possible 
A usable 
model to 
obtain a 
prediction  
from a 
chemical 
structure is 
preferred 
Influence as the 
ease of use of a 
model will influence 
if and how a user 
applies it 
 
Bias in the choice of 
the models 
implemented in the 
software may be 
biased by the sector 
for which the 
software is intended 
for 
No 
3.2b Software 
accessibility 
Software is publicly 
and freely available  
Software may be 
obtained on specific 
license  
Software is not 
publicly 
available, e.g. 
in-house 
software 
 Influence relating to 
software 
accessibility of a 
model will influence 
if and how a user 
applies it 
  
No 
3.2c Software 
transparency 
Software algorithm 
transparent 
Design of software 
and implementation 
of model 
transparent, but not 
the code 
Closed software 
which cannot be 
examined 
 Uncertainty about 
model if details not 
known, lower 
confidence in a 
model associated 
with software  
perceived as a 
“black box”  
 
Influence as a user 
may not wish to use 
No 
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non-transparent 
software 
3.2d Relative cost Free / cheap to use 
compared to a 
standard test 
Moderate cost and / 
or need for licencing 
Cost equivalent 
or greater than 
a standard test 
 Influence where a 
user may have 
budget constraints 
that pre-determine 
which models can / 
cannot be used 
No 
3.2e Sustainability Strong sustainability 
plan 
Model available 
from a reliable 
source e.g. 
governmental web-
site, but without 
published 
sustainability 
planning 
No obvious 
sustainability 
e.g. a model on 
a freely 
available web-
site, which 
might disappear 
at any time  
 Influence as a user 
may prefer the use 
of a model with 
assurance that it 
will be available in 
the future 
No 
3.2f Maintenance and 
support 
Strong maintenance 
plan and good 
product support 
Limited possibility 
for maintenance and 
/ or support 
No obvious 
maintenance or 
support, or 
technical 
implementation 
is not updated 
Software that 
is not 
maintained 
and updated 
could become 
redundant 
Influence as a user 
may prefer a well 
maintained and 
supported product  
No 
3.2g Intellectual 
Property (IP) 
No IP limitations, i.e. 
open access with e.g. 
appropriate Creative 
Commons license 
IP, but available via 
license  
IP restrictive to 
use of the 
model 
 Influence as a user 
may preferentially 
wish to use (or 
develop further) a 
model without IP 
restrictions 
No 
3.2h Ownership Model ownership 
defined and contact 
provided 
Ownership known, 
but no contact 
information or 
availability 
Ownership not 
known 
 Influence as a user 
may prefer a model 
with known 
ownership (e.g. to 
obtain more 
Yes 
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information, or to 
trust the source as 
perceived as being 
reliable) 
3.2i Ethics No ethical concerns Minor ethical 
concerns e.g. use of 
animal data without 
fully reported ethics 
Ethical concerns 
about 
development or 
use of model 
This may relate 
to the data e.g. 
animal tests or 
data 
protection 
issues 
Influence as a user 
may prefer to use a 
model with known 
ethical pedigree 
No 
        
3.3 Applicability, Relevance and Adequacy  
        
3.3a Heterogeneity and 
density of chemical 
space of the model 
for the chemical for 
which a prediction 
is required (related 
to Criteria 1.4d) 
Prediction being 
made in an area of 
the applicability 
domain that has a 
high density of 
potentially similar 
compounds 
Prediction being 
made in an area of 
the applicability 
domain that has a 
moderate density of 
potentially similar 
compounds 
Prediction being 
made in an area 
of the 
applicability 
domain that has 
a low density of 
potentially 
similar 
compounds or 
density not 
known 
 Uncertainty about 
the applicability of 
the model for 
considered target 
chemical 
No 
3.3b Relevance of the 
predicted endpoint 
for the regulatory 
risk assessment 
purpose/protection 
goal 
Predicted endpoint 
related directly to the 
(regulatory) endpoint 
of interest and 
relevant for overall 
assessment purpose 
Predicted endpoint 
generally relevant 
for the regulatory 
endpoint 
considered, might 
contribute to 
insights, but does 
not provide 
sufficient evidence 
Not relevant to 
considered 
endpoint or 
stated purpose 
 Uncertainty about 
the relevance of the 
model for the risk 
assessment, 
purpose or 
regulatory endpoint  
Yes 
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to fulfil overall 
stated risk 
assessment purpose  
3.3c Adequacy of the 
model to make a 
prediction for the 
stated (regulatory) 
purpose 
Prediction is 
adequate for the 
stated purpose 
Prediction is 
adequate for the 
considered endpoint 
generally, but not 
for the particular 
regulatory purpose 
(for example 
classification and 
labelling)  
Not adequate 
for stated 
purpose 
Adequacy is a 
function of the 
information 
and 
confidence 
required for a 
prediction in a 
certain set of 
circumstance. 
There are 
many potential 
uses for the 
same model 
and the 
acceptability 
and adequacy 
of a prediction 
might be 
different for 
them. 
Uncertainty about 
the adequacy of the 
model for a specific 
purpose  
No 
3.3d Extrapolation and 
relevance to 
humans 
Relevance for 
humans generally 
agreed or 
demonstrated based 
on same biological 
pathways etc. 
Potentially relevant 
to humans e.g. 
predictive of effects 
to a non-human 
mammalian species  
Not relevant  Uncertainty about 
the relevance of a 
model to human 
health   
Yes 
3.3e Extrapolation and 
relevance to 
environmental 
biota 
Relevance to 
environmental biota 
generally agreed or 
demonstrated based 
Partially relevant to 
environmental biota 
Not relevant to 
environmental 
biota 
 Uncertainty about 
the relevance of a 
model to 
environmental biota  
Yes 
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on same biological 
pathways etc. 
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The list of assessment criteria can be used for the evaluation of a QSAR model in a systematic way, in 
order to identify key uncertainties. The practical application of the assessment criteria in Tables 3-5 
requires a thorough analysis of the QSAR model but also a use case scenario or problem formulation. 
As noted, some of the information can be obtained from a well-developed QMRF (see Tables 3-5). 
Other information requires expert judgement and detailed assessment of the QSAR model. In order 
to put the assessment criteria in the context of the OECD Principles for the Validation of QSARs the 
relevant criteria have been mapped onto the individual Principles, as shown in Table 6. This analysis 
also demonstrates that the assessment criteria cover many other aspects of QSAR models which are 
also summarised in Table 6. The assessment criteria allow for a greater understanding of where 
uncertainties in particular affect the application of QSARs for a particular purpose and what factors 
might also have an influence, thus extending the concept of an assessment or even formal validation 
of a QSAR to whether individual predictions may be appropriate for a specific purpose and how they 
could be improved.  
Table 6. Mapping of the assessment criteria in Tables 3-5 onto the OECD Principles of the Validation 
of QSARs or other topics not addressed specifically or wholly by the OECD Principles. 
OECD Principles Assessment Criteria in 
Tables 3-5 
  
1) a defined endpoint 1.2e, 3.3b, 3.3c, 3.3d, 3.3e 
2) an unambiguous algorithm 2.1a, 2.1b, 2.1c 
3) a defined domain of applicability 2.3a, 2.3b, 2.3c 
4) appropriate measures of goodness-of–fit, robustness and predictivity 1.4e, 2.2a 
5) a mechanistic interpretation, if possible 2.4a 
  
Other Issues Not Necessarily Captured by the OECD Principles   
  
Data quality and curation 1.1a, 1.1b, 1.2a, 1.2b, 1.2c, 
1.2d, 1.2f, 1.4b, 2.2b 
Model / descriptors  1.3a, 1.3b, 1.3c, 1.3d, 1.3e, 
1.4a 
ADME and toxicokinetics considerations 1.2g, 2.5a, 2.5b 
Bias in QSAR development 1.4c, 1.5a, 3.3a 
Details of the documentation of the model 1.4d, 2.4b, 2.4c, 3.1a 
Practical use of the QSAR and relevance / adequacy for regulatory 
application 
3.1b, 3.2a, 3.2b, 3.2c, 3.2d, 
3.2e, 3.2f, 3.2g, 3.2h, 3.2i 
 
Two case studies applying the assessment criteria to QSARs representing different model types have 
been performed. The results of the evaluation with the assessment criteria are reported in the 
Supplementary Information. The assessment criteria were applied rapidly in the case studies as would 
be the case for a quick routine assessment of the usability of a model in a broader risk evaluation 
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exercise. Each criterion can be scored with a scoring system of “high, moderate or low” uncertainty, 
variability, bias or area of influence being used in this analysis. According to user requirements, the 
scoring system may be annotated to explain any particular decision. However, the scoring scheme is 
intended to be user-defined and whatever scoring scheme is employed, it should be flexible and 
adaptable. It is not intended to give an overall score of uncertainty, variability, bias or influence in this 
way but to highlight potential areas where further consideration may be required.  
Table S1 gives the findings for a simple log P regression-based QSAR and Table S2 for the in silico 
workflow for nuclear receptor binding. As well as assigning uncertainties, variabilities and areas of 
biases and influences Tables S1 and S2 also include a brief comment and explanation which will be 
especially important to explain a decision. The outcome of the analysis detailed in Table S1 for Case 
Study 1 is summarised in Table 7. This shows that the greatest uncertainties relate to the use of a non-
standard test with historical protocols although existing knowledge is presented that may reduce 
uncertainty (Cronin et al., 1991; Hewitt et al., 2011). Likewise, the analysis in Table S2 for Case Study 
2 is summarised in Table 8 showing uncertainty with biological data quality and its relevance. Such 
analyses also provide an opportunity to identify mitigation strategies that can help to reduce (if 
possible) uncertainty. The intention of the mitigation strategies is to allow for resources to be directed 
to improve the use and relevance of QSAR models. 
Table 7. Summary analysis of the analysis of the criteria for uncertainty, variability, bias and 
influence (as reported in Table S1), as a means to highlight possible areas for improvement, for Case 
Study 1: QSAR for the inhibition of growth of non-polar narcotics to Tetrahymena pyriformis. 
Number of 
Criteria with low 
uncertainty, 
variability, bias, 
influence 
Number of 
Criteria with 
moderate 
uncertainty, 
variability, bias, 
influence 
Number of 
Criteria with high 
uncertainty, 
variability, bias, 
influence 
Number of Criteria Not Considered 
36 3 2 8 
 
Main Areas of 
Uncertainty 
Relating to 
Criteria 
Mitigation Strategy 
 
Biological data 
quality 
1.2a, 1.2f, 1.2g Biological data are historical but well characterised (Hewitt et 
al., 2011). They are shown to relate strongly to e.g. fish 
toxicity (Cronin et al., 1991). It is unlikely that internal 
concentrations will be calculated and this must be borne in 
mind if predictions are used. 
No training / test 
set 
1.4e Model could be redeveloped with a training / test set 
Model not 
implemented  
3.2a Model could be implemented in appropriate software 
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Table 8. Summary analysis of the analysis of the criteria for uncertainty, variability, bias and 
influence (as reported in Table S2), as a means to highlight possible areas for improvement, for Case 
Study 2: In silico workflow for nuclear receptor binding leading to hepatic steatosis. 
Number of 
Criteria with low 
uncertainty, 
variability, bias, 
influence 
Number of 
Criteria with 
moderate 
uncertainty, 
variability, bias, 
influence 
Number of 
Criteria with high 
uncertainty, 
variability, bias, 
influence 
Number of Criteria Not Considered 
30 7 9 3 
    
Main Areas of 
Uncertainty 
Relating to 
Criteria 
Mitigation Strategy 
 
Biological data 
quality 
1.1b, 1.2a, 1.2b, 
1.2c, 1.2d, 1.2e, 
1.2f, 1.2g 
Biological data are historical but well characterised. 
Further analysis of the original source data / 
publications could assist in understanding and 
confirming data quality. It is unlikely that internal 
concentrations will be calculated and this must be 
borne in mind if predictions are used. 
No training / test 
set 
1.4e Model could be redeveloped with a training / test set 
Reporting of 
statistical 
performance 
2.2a, 2.2b Re-analysis of the models could be performed to 
determine statistical performance 
Relevance of the 
endpoint 
modelled 
2.3c, 3.3d More information could be provided, e.g. via a relevant 
AOP, to demonstrate relevance 
ADME and TK 
consideration 
2.5a, 2.5b A greater consideration of metabolic stability and 
relevance of toxicokinetics could be provided 
Lack of 
maintenance and 
support 
3.2f A maintenance and support plan could be initiated  
 
 
With the application of the assessment criteria reported in Tables 3-5 it is important to recognise the 
purpose of the analysis. The primary purpose is to identify uncertainties or areas of variability and / 
or bias and influence in a QSAR. The intent of the identification of these areas is two-fold. Firstly, to 
alert the user to potential limitations in the use of a QSAR for a specific purpose, the limitations 
identified can then be considered on an individual basis in the context of the use of the prediction. For 
example, in Case Study 1, analysis of the first thematic area (i.e., Model Creation) indicates that 
assessment criteria 1.2a and 1.4d each have moderate uncertainty as a result of the data being derived 
from a non-standard test and data were not split into training and test sets, respectively. However, 
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since the Tetrahymena population growth inhibition testing was performed to a rigorous Standard 
Operating Procedure (SOP) and the QSAR was developed with a tightly defined applicability domain, 
this uncertainty is likely to be acceptable. Similarly, for Case Study 1, assessment criteria 1.1f and 1.1g 
have high uncertainty as the potency data were based on nominal concentrations and internal 
exposure is not known, respectively. If the predictions from such a QSAR are used in a weight-of-
evidence to support aquatic toxicity predictions, these uncertainties are likely be deemed 
unimportant; however, such uncertainty may be significant for different types of use. The second 
intent of the identification of uncertainties is to establish how QSARs may be improved through the 
inclusion of further information or data such that key areas of concern can be improved (e.g., 
uncertainties reduced). Other criteria listed in Table 5 in particular allow for the highlighting of 
potential problems or barriers to the actual application of the models and for the raising of awareness 
of the issues which relate to the uptake of models in practice. For the use of QSARS in regulatory 
applications, the relevant criteria for the type of risk assessment and legislative context considered 
are particularly important to evaluate. 
With regard to the application of the assessment criteria in Tables 3-5, the proposal is to use these 
criteria to assess uncertainty and other issues in terms of a low – moderate – high semi-quantitative 
scheme. As noted above, this may provide a means to extend the general concepts and discussion of 
validation of QSARs (OECD, 2007) and provides specific criteria where pre-defined measures for each 
are applied. The exact application of these criteria, setting of possible pre-defined measures of 
“acceptability” and inculcation into regulatory frameworks, however, goes beyond the scope of this 
paper or the capabilities of the authors alone – this is a topic that should be addressed with open 
dialogue in the QSAR modelling and regulatory risk assessment communities to facilitate international 
regulatory uptake. There is no reason not to suppose that other scoring schemes could be applied (e.g. 
as discussed by Schultz et al (2015)) or that uncertainty could be classified as simply acceptable or not 
acceptable. It would seem that a classification scheme is, however, preferable and that a three-step 
scale from low to high is pragmatic. In addition, this type of classification scheme would lend itself to 
a traffic light-style of presentation (as in Tables S1 and S2), or even a summary presentation (as 
illustrated in the Graphical Abstract). In part, this type of assessment will inform about the adequacy, 
or otherwise, of a model for a particular purpose, in the same manner as QSAR reporting formats 
currently used, and may assist in utilisation of QSAR predictions, for instance in accordance with 
guidance proposed ECHA (2011 – Section R4.3.2). However, future effort should be placed into the 
development of quantitative uncertainty analysis to determine whether a prediction from a QSAR is 
acceptable or not for a specific regulatory purpose – especially in light of the unified frameworks 
currently available for hazard characterisation (WHO IPCS, 2014; Chui and Slob, 2015). In addition, 
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such an overview of the model, as proposed by the assessment criteria, would allow the user or 
regulator to quickly grasp any potential areas of concern, which need to be looked into further, and 
thus contribute to support making an informed decision on the adequateness of the model for the 
intended purpose – keeping in mind that the relevance of the model has to be verified depending on 
the endpoint and hazard/risk assessment goal in question.   
 
Conclusions 
The uncertainties and areas of variability, biases and influence of QSAR models have been identified 
and a set of assessment criteria to evaluate QSAR models is presented. In total 49 assessment criteria 
have been defined to account for aspects of the data behind the model and the model development 
approach, the description of the model and its application. The criteria allow for the identification of 
areas of high uncertainty or other issues that may be of concern for the confidence in a particular 
prediction or use of a model and also point towards issues which might influence or prevent the 
update of models in practice. Application of the assessment criteria could allow for mitigation 
strategies to be proposed. The assessment criteria are not intended as a means to rank models in 
terms of their suitability, and should not be seen, or utilised in that way. However, the criteria are 
intended to make users of a model aware of the potential areas of uncertainty and / or variability and 
bias and to provide them an opportunity to reduce them, as well as to make an informed decision on 
their impact and on the adequateness of use of the model for the intended purpose. In addition, the 
criteria may provide a stepping stone towards the validation of models.  
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Table S1. Case Study 1: Application of assessment criteria in Tables 3-5 to a QSAR for non-polar narcosis to Tetrahymena pyriformis 
Low Uncertainty, Variability, Bias or Influence  
Moderate Uncertainty, Variability, Bias or Influence  
High Uncertainty, Variability, Bias or Influence  
 
ID Area of Uncertainty, Variability, Bias or Influence Assignment of 
Uncertainty, 
Variability, Bias or 
Influence 
Reason 
    
1. Model Creation 
    
1.1 Definition of Chemical Structures 
    
1.1a Accuracy of chemical structure  Structures unambiguously defined including any isomerism   
1.1b Assessment of significant impurities or mixtures   Impurities / mixtures defined and stated 
    
1.2 Biological Data 
    
1.2a Quality of individual studies in the data set  Non-standard test, although performed to a rigorous SOP 
1.2b Consistency of the data set including comparability of 
data 
 Consistent set in terms of assay, same laboratory 
1.2c Checking of toxicological data  Source data / study reports checked 
1.2d Error associated with biological data  Error is known and stated. There is a publication on the 
experimental variability.  
1.2e (if required) Units of concentration known, stated 
and appropriate for use 
 Appropriate units stated 
1.2f (If appropriate) Nominal or measured concentrations   Nominal concentrations used 
1.2g Internal exposure known  internal exposure is not known 
    
1.3 Measurement and / or Estimation of Physico-Chemical Properties and Structural Descriptors 
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1.3a Measurement of physico-chemical properties N/A Measured properties not used 
1.3b Calculation of properties and 2-D descriptors  Well characterised software providing unambiguous properties 
1.3c Calculation of 3-D descriptors N/A 3-D descriptors not utilised 
1.3d Software utilised   Full details of software provided 
1.3e Definition of molecular fragments N/A Molecular fragments not used in model (but used to define the 
applicability) 
    
1.4 Creation of the Data Set for QSAR Modelling 
    
1.4a Data set is complete  Full data set provided 
1.4b Data set has appropriate variation in potency 
(quantitative) or balance of actives vs inactives 
(qualitative) 
 Good variation in potency (e.g. several log units) 
1.4c Selection of training set data  Training set selected without bias 
1.4d Training set homogeneity  Training set is homogeneous 
1.4e Suitable training and test sets defined and utilised  No splitting into training and test set, although QSAR developed as 
much for the applicability domain as the model 
    
1.5 Modelling Approach 
    
1.5a How appropriate is the modelling approach for the 
endpoint and to deal with the complexity / non-
linearity of the data 
 Regression analysis is an appropriate modelling approach for the 
endpoint 
    
2. Description of the QSAR Model 
    
2.1 Description of Model 
    
2.1a Documentation and reporting  Model fully defined 
2.1b Data set is complete and described  No data gaps 
2.1c Transparency of the model  Model is transparent in terms of the algorithm 
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2.2 Statistical Performance 
    
2.2a Statement of statistical fit, performance and 
predictivity  
 Full description of model performance 
2.2b Interpretation of statistical fit etc with respect to 
biological error (see Criterion 1.2d)  
 Statistical performance is significant but not overfitted 
    
2.3 Applicability Domains 
    
2.3a Chemical applicability domain of model  Fully defined in terms of relevant physico-chemical properties and 
structure 
2.3b Mechanistic applicability domain of model  Fully defined in terms of relevant mechanism(s) of action 
2.3c Biological applicability domain of model  Fully defined including possible metabolism 
    
2.4 Mechanistic Relevance, Interpretability and Transparency 
    
2.4a Mechanistic justification  Definition of non-polar narcosis mechanism of action  
2.4b Presence / availability of other and supporting 
information 
 Use of evidence relating to mechanistic basis 
2.4c Relevance to descriptors to mechanism of action / 
AOP 
 Descriptors or properties clearly related to mechanism 
    
2.5 Adequate coverage of ADME effects 
    
2.5a Metabolism and / or effect of significant metabolites 
have been considered 
 Role of metabolism in eliciting the toxicity is established 
2.5b Toxicokinetics have been addressed in the model  Model relates to toxicokinetic considerations that affect toxicity or 
potency 
    
3. Application of the QSAR Model 
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3.1 Documentation and Reproducibility 
    
3.1a Reproducibility of the models  Model transparent and fully documented 
3.1b Reproducibility of the prediction N/A No predictions made 
    
3.2 Usability 
    
3.2a Implementation of the model  Not implemented into software but it could be possible 
3.2b Software accessibility N/A No software utilised 
3.2c Software transparency N/A No software utilised 
3.2d Relative cost  Cheap to use compared to a standard test 
3.2e Sustainability  Published QSAR 
3.2f Maintenance and support N/A No software provided 
3.2g Intellectual Property  No IP considerations i.e. open access  
3.2h Ownership  Model in public domain  
3.21 Ethics  No ethical concerns 
    
3.3 Relevance 
    
3.3a Heterogeneity and density of chemical space  Well populated and distributed chemical space 
3.3b Relevance of the predicted endpoint for the 
regulatory risk assessment purpose/protection goal 
 Fit for stated purpose. Likely to provide an estimate that could 
support e.g. hazard identification. 
3.3c Adequacy  Adequate for stated purpose. Likely to provide an estimate that 
could support e.g. hazard identification. 
3.3d Extrapolation and relevance to humans N/A Not for humans  
3.3.e Extrapolation and relevance to environmental biota  Relevant to environmental biota 
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Table S2. Case Study 2: Application of assessment criteria in Tables 3-5 to an in silico workflow to identify nuclear receptor binders that may be related to 
hepatic steatosis. 
Low Uncertainty, Variability, Bias or Influence  
Moderate Uncertainty, Variability, Bias or Influence  
High Uncertainty, Variability, Bias or Influence  
 
ID Area of Uncertainty, Variability, Bias or Influence Assignment of 
Uncertainty, 
Variability, Bias or 
Influence 
Reason 
    
1. Model Creation 
    
1.1 Definition of Chemical Structures 
    
1.1a Accuracy of chemical structure  Structures unambiguously defined including any isomerism   
1.1b Assessment of significant impurities or mixtures   Impurities / mixtures not known 
    
1.2 Biological Data 
    
1.2a Quality of individual studies in the data set  Non-standard test, quality of individual studies not known 
1.2b Consistency of the data set including comparability 
of data 
 Same / similar assays and endpoints but performed in different 
laboratories  
1.2c Checking of toxicological data  Source data not checked but used as provided in ChEMBL 
1.2d Error associated with biological data  Unknown error  
1.2e (if required) Units of concentration known, stated 
and appropriate for use 
 ChEMBL units applied (not molar) 
1.2f (If appropriate) Nominal or measured concentrations   Nominal concentrations used 
1.2g Internal exposure known  internal exposure is not known 
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1.3 Measurement and / or Estimation of Physico-Chemical Properties and Structural Descriptors 
    
1.3a Measurement of physico-chemical properties N/A Measured properties not used 
1.3b Calculation of properties and 2-D descriptors  Well characterised software providing unambiguous properties 
1.3c Calculation of 3-D descriptors N/A 3-D descriptors not utilised 
1.3d Software utilised   Full details of software provided 
1.3e Definition of molecular fragments  Molecular fragments well defined 
    
1.4 Creation of the Data Set for QSAR Modelling 
    
1.4a Data set is complete  Full data set provided 
1.4b Data set has appropriate variation in potency 
(quantitative) or balance of actives vs inactives 
(qualitative) 
 Good variation in potency (e.g. several log units) 
1.4c Selection of training set data  Training set selected without bias 
1.4d Training set homogeneity  Training set is homogeneous 
1.4e Suitable training and test sets defined and utilised  No splitting into training and test set, although QSAR developed as 
much for the applicability domain as the model 
    
1.5 Modelling Approach 
    
1.5a How appropriate is the modelling approach for the 
endpoint and to deal with the complexity / non-
linearity of the data 
 Regression analysis is an appropriate modelling approach for the 
endpoint 
    
2. Description of the QSAR Model 
    
2.1 Description of Model 
    
2.1a Documentation and reporting  Model fully defined 
2.1b Data set is complete and described  No data gaps 
2.1c Transparency of the model  Model is transparent in terms of the algorithm 
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2.2 Statistical Performance 
    
2.2a Statement of statistical fit, performance and 
predictivity  
 Limited evaluation of statistical performance 
2.2b Interpretation of statistical fit etc with respect to 
biological error (see Criterion 1.2d)  
 Statistical performance is significant, possibly over-predictive 
    
2.3 Applicability Domains 
    
2.3a Chemical applicability domain of model  Fully defined in terms of relevant physico-chemical properties and 
structure 
2.3b Mechanistic applicability domain of model  Fully defined in terms of relevant mechanism(s) of action 
2.3c Biological applicability domain of model  Binding data may not have biological relevance 
    
2.4 Mechanistic Relevance, Interpretability and Transparency 
    
2.4a Mechanistic justification  Definition of nuclear receptor binding  
2.4b Presence / availability of other and supporting 
information 
 Use of evidence relating to mechanistic basis 
2.4c Relevance to descriptors to mechanism of action / 
AOP 
 Descriptors or properties clearly related to mechanism 
    
2.5 Adequate coverage of ADME effects 
    
2.5a Metabolism and / or effect of significant metabolites 
have been considered 
 Role of metabolism not addressed 
2.5b Toxicokinetics have been addressed in the model  Model does not relate to toxicokinetic considerations  
    
3. Application of the QSAR Model 
    
3.1 Documentation and Reproducibility 
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3.1a Reproducibility of the models  Model transparent and fully documented 
3.1b Reproducibility of the prediction N/A No predictions made 
    
3.2 Usability 
    
3.2a Implementation of the model  Model implemented ina a KNIME Workflow 
3.2b Software accessibility  KNIME and relevant nodes freely available; as is workflow 
3.2c Software transparency  KNIME and relevant nodes freely transparent; as is workflow 
3.2d Relative cost  Cheap to use compared to a standard test 
3.2e Sustainability  Published QSAR 
3.2f Maintenance and support  Free software with no maintenance and support 
3.2g Intellectual Property  No IP considerations i.e. open access  
3.2h Ownership  Model in public domain  
3.2i Ethics  No ethical concerns due to use of an in vitro assay 
    
3.3 Relevance 
    
3.3a Heterogeneity and density of chemical space  Well populated and distributed chemical space 
3.3b Relevance of the predicted endpoint for the 
regulatory risk assessment purpose/protection goal 
 Fit for stated purpose. Likely to provide an estimate that could 
support e.g. hazard identification 
3.3c Adequacy  Adequate for stated purpose. Likely to provide an estimate that 
could support e.g. hazard identification. 
3.3d Extrapolation and relevance to humans  Possible relevance for humans  
3.3e Extrapolation and relevance to environmental biota  Relevant to environmental biota 
    
 
 
 
